Semaglutide Prolonged the Lifespan of Aged Female Mice by 12%, According to a Study

A study on aged C57BL/6 female mice found that semaglutide reduced caloric intake by 24% and extended lifespan by approximately 12%, with effects similar to caloric restriction on various aging markers. Researchers caution that prolonged clinical studies are still needed to determine if this benefit can be translated to humans.

• The treatment began when the mice were 20 months old and reduced their food intake by 24%.
• The mice lived approximately 12% longer and showed improvements in physiological function, inflammation, and neuronal health.
• Comparison with an equivalent caloric restriction produced similar results, although the drug prevented the constant feeling of hunger.

An Effect Associated with Eating Less

The treatment with semaglutide extended the lifespan of aged female mice by approximately 12% and improved several indicators of their physiological state, according to information published by Fight Aging! regarding a study on GLP-1 receptor activation. The participants were C57BL/6 mice aged 20 months, an advanced age for the model used, and they received a defined regimen that reduced their food intake by 24%. In absolute terms, the median survival was 834 days with semaglutide, compared to 742 days in the control group. This result places the drug within a broader discussion about metabolism, aging, and caloric restriction.

GLP-1 receptor agonists, including semaglutide, reduce appetite and are often associated with lower food consumption. This characteristic complicates the interpretation of any longevity results because caloric restriction without nutritional deficiencies has already been shown to slow aging and prolong life in various animal experiments. Therefore, a significant part of the observed effect could simply stem from the fact that the mice ate less, rather than revealing a completely new mechanism linked to the GLP-1 receptor.

Caloric restriction limits the availability of nutrients and activates metabolic responses that researchers have known for decades. Hunger, however, also generates its own signals, distinct from those produced directly by cells when they detect their nutrient levels, so a drug that reduces appetite does not necessarily replicate all aspects of a limited diet. This difference was relevant for the design of the experiment and for interpreting its results on aging.

The researchers selected only females to reduce potential confounding factors related to aggression and injury among males, a decision consistent with prolonged aging studies. Among the monitored results, the team did not identify adverse effects attributable to semaglutide. Nevertheless, the design does not allow for concluding that the drug prolongs human life or that its benefits are independent of reduced caloric intake.

What Changed in Aged Mice

The study described a broad improvement in age-related deterioration after activating GLP-1R in the mice. The effects included better physiological function and a reduction in markers related to stem cell loss, inflammation, cellular senescence, genomic instability, mitochondrial dysfunction, and proteostasis deterioration, the system that helps maintain protein quality. Collectively, these findings point to an intervention that affected multiple biological pathways simultaneously.

Changes were also observed in genetic regulators of aging and nutrient sensors, with patterns that researchers described as similar to those produced by caloric restriction. The concept of caloric restriction mimetics is used to describe treatments that reproduce some of its biological responses without requiring a voluntary and sustained reduction in food intake. In this case, the similarity does not rule out the possibility that semaglutide acts on metabolic processes that a restricted diet does not modify in the same way.

One of the most notable findings appeared in the nervous system. Activation of the GLP-1 receptor restored neural stem cells and increased neurogenesis in aged female mice, an effect particularly relevant given the emerging evidence about the possible link between these medications and certain neurodegenerative processes. The study does not turn that finding into a therapy for human diseases, but it does expand scientific interest in the effects of GLP-1 beyond glucose and weight control.

The research also included a direct comparison with a group subjected to caloric restriction equivalent to the reduction in intake caused by semaglutide. Health outcomes were very similar in several aspects of the physiological decline associated with age, a coincidence that supports the hypothesis that the drug works, at least in part, as a caloric restriction mimetic. The comparison also left open metabolic differences that will require more detailed analysis.

The Difference Between a Drug and a Diet

The main practical difference between the two approaches was in the sensation of hunger. Mice subjected to caloric restriction remained hungry for much of the time, while those treated with a GLP-1 agonist reduced their intake by suppressing appetite. This variation matters because the signals associated with hunger influence metabolism through pathways that are not identical to those activated by cellular detection of nutrients.

The contrast prevents summarizing the result as definitive proof that semaglutide is an anti-aging drug. If food reduction explains a substantial part of the increased longevity, the experiment would primarily confirm that the drug can induce a metabolic condition similar to caloric restriction in old mice. To demonstrate an additional mechanism, designs capable of separating the effect of eating less from the specific effect of activating GLP-1R would be necessary.

The pleiotropic benefits attributed to GLP-1R activation include better glucose and weight control, as well as a lower burden of cardiovascular, renal, hepatic, and neurodegenerative diseases in mouse models and clinical studies. However, the existence of clinical benefits in those areas does not automatically demonstrate that the treatment modifies the trajectory of aging. Longevity and biological markers of aging would need to become explicit targets of prolonged studies.

The work raises a relevant possibility for medicine: if aging constitutes the greatest risk factor for numerous chronic diseases, an intervention that slows it down could simultaneously influence seemingly unrelated problems. That possibility remains a hypothesis derived from an animal model, not a recommendation to use semaglutide for longevity purposes. The answer will depend on research that follows older individuals for years and evaluates aging outcomes with defined criteria.

What Still Cannot Be Concluded

The results correspond to female mice of a specific strain and a specific treatment regimen initiated in old age. Differences between species, sex, dosage, duration, and metabolic conditions can alter both the response to the medication and the relationship between caloric intake and longevity. For this reason, extrapolating the approximate 12% increase to humans would be scientifically unjustified with the available information.

The study does provide a basis for investigating why a medication that reduces appetite may influence such diverse cellular processes. The reduction of inflammation, senescence, mitochondrial dysfunction, and genomic instability suggests a systemic response, although each marker requires specific analysis to establish whether it causes the improvement or simply accompanies a better metabolic state. In particular, the neural results justify further investigations but do not prove prevention or treatment of neurodegeneration in humans.

Fight Aging! noted that GLP-1 medications are widely used in clinical practice but also emphasized that the activation of GLP-1R can only be linked to changes in human aging through long-term clinical studies. These trials would need to include older populations and measure not only weight or glucose but also physiological function, age-related diseases, quality of life, and survival. Without that evidence, the finding must remain in the preclinical realm.

For now, the strongest conclusion is that semaglutide reproduced in aging female mice several molecular and physiological benefits of equivalent caloric restriction while reducing the hunger that accompanies a limited diet. The discovery is promising for aging research but does not turn the drug into a guarantee of longer life for humans.

This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.